Calyxt Inc (NASDAQ:CLXT) CEO James Blome sold 3,495 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.65, for a total value of $16,251.75. Following the completion of the transaction, the chief executive officer now owns 198,057 shares in the company, valued at approximately $920,965.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

James Blome also recently made the following trade(s):

  • On Monday, June 29th, James Blome sold 2,902 shares of Calyxt stock. The stock was sold at an average price of $5.01, for a total value of $14,539.02.

CLXT opened at $4.41 on Friday. Calyxt Inc has a 1-year low of $2.40 and a 1-year high of $9.77. The company has a debt-to-equity ratio of 0.35, a current ratio of 9.38 and a quick ratio of 8.80. The business has a 50 day moving average of $4.90 and a 200-day moving average of $4.85.

Calyxt (NASDAQ:CLXT) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Calyxt had a negative net margin of 455.07% and a negative return on equity of 64.78%. The business had revenue of $2.38 million during the quarter. Equities research analysts predict that Calyxt Inc will post -1.22 earnings per share for the current fiscal year.

CLXT has been the topic of a number of research reports. Zacks Investment Research downgraded Calyxt from a “buy” rating to a “hold” rating in a report on Monday, June 8th. Wells Fargo & Co decreased their target price on Calyxt from $6.00 to $4.00 and set an “equal weight” rating for the company in a research report on Friday, May 15th. Canaccord Genuity started coverage on Calyxt in a research report on Tuesday, July 28th. They set a “buy” rating and a $8.00 target price for the company. BMO Capital Markets cut Calyxt from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $13.00 to $7.00 in a research report on Friday, May 8th. Finally, National Securities reaffirmed a “buy” rating and set a $10.00 target price on shares of Calyxt in a research report on Friday, May 8th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $6.88.

Institutional investors and hedge funds have recently bought and sold shares of the company. Oppenheimer & Co. Inc. bought a new position in Calyxt in the first quarter worth $47,000. Two Sigma Investments LP bought a new position in Calyxt in the first quarter worth $61,000. Bank of New York Mellon Corp lifted its position in Calyxt by 15.8% in the first quarter. Bank of New York Mellon Corp now owns 26,097 shares of the company’s stock worth $86,000 after purchasing an additional 3,563 shares during the period. UBS Group AG lifted its position in Calyxt by 40.4% in the fourth quarter. UBS Group AG now owns 14,296 shares of the company’s stock worth $100,000 after purchasing an additional 4,116 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Calyxt by 26.9% in the first quarter. Wells Fargo & Company MN now owns 45,933 shares of the company’s stock worth $153,000 after purchasing an additional 9,733 shares during the period. 23.93% of the stock is owned by institutional investors.

About Calyxt

Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes.

See Also: CD Ladder

Insider Buying and Selling by Quarter for Calyxt (NASDAQ:CLXT)

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.